Evidence Sheet: Dow (DOW)
The standing BullScope yardsticks for Dow, computed from official filings and refreshed with each new edition.
Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.
The standing BullScope yardsticks for Dow, computed from official filings and refreshed with each new edition.
A single-digit earnings multiple is what the market assigns to a business in slow decline. A mid-single-digit sales multiple is...
Six years ago, Disney was the most expensive media stock on earth, and investors were happy to pay for the...
Three years ago, AbbVie's biggest drug lost its U.S. patent protection and the company braced for a revenue cliff. Humira,...
In one breath The Q2 2026 10-Q shows revenue up sharply and a backlog worth more than four years of...
The standing BullScope yardsticks for American Airlines Group, computed from official filings and refreshed with each new edition.
In one breath The U.S. economy shed 23,000 jobs in July 2026, according to the BLS report released August 7,...
The standing BullScope yardsticks for Eli Lilly &, computed from official filings and refreshed with each new edition.
In one breath Eli Lilly's Q2 2026 10-Q confirms revenue nearly doubling in two years, with two weight-loss drugs now...
In one breath Eli Lilly's revenue has more than doubled in two years, and its profit margin is now the...
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer